Physician profile
Sean Baker
NPI 1508060641
$2,422.80
in general payments reported to CMS, 2019-2025
27 companies · $93.14 in 2025
The $93.14 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $457 · 2021: $237 · 2022: $434 · 2023: $261 · 2024: $61.72 · 2025: $93.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $438.58 | 2020-2023 | Qulipta, Ubrelvy, Linzess |
| Amgen INC. | $310.71 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $179.87 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $177.98 | 2019-2020 | |
| Abbott Laboratories | $165.80 | 2020-2025 | Freestyle Libre, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $141.68 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $141.01 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $124.92 | 2019-2020 | |
| Astellas Pharma US INC | $87.33 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $69.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $53.85 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.47 | 2022 | |
| Amarin Pharma, INC. | $49.72 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $49.11 | 2019-2020 | |
| Acclarent, INC | $40.24 | 2023 | Trudi Nav Cable |
| Lilly USA, LLC | $27.30 | 2019-2025 | Zepbound, Mounjaro |
| Supernus Pharmaceuticals, INC. | $24.93 | 2020-2021 | |
| Sanofi Pasteur INC. | $24.56 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $23.49 | 2023-2024 | Gemtesa |
| Corium, LLC | $20.10 | 2022 | |
| Radius Health, INC. | $19.70 | 2019 | |
| Esperion Therapeutics, INC. | $17.48 | 2022 | |
| Boston Scientific Corporation | $14.87 | 2023 | Watchman Access System |
| Ibsa Pharma INC. | $14.10 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.